Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00420706 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating SCA-136 Tolerability With Dose Titration and Food
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT00420706 is a Phase 1 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 120 participants.
The verdict
NCT00420706, a Phase 1 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
To evaluate whether the tolerability of SCA-136 is improved by dosing with food or by increasing dose amounts in a step-wise fashion.
Interventions
- DRUG SCA-136
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2006-12 |
| Est. Completion | 2006-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00420706
The ClinicalTrials.gov registry entry for NCT00420706 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SCA-136 is the first listed.
NCT00420706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00420706 about?
NCT00420706 is a clinical study titled "Study Evaluating SCA-136 Tolerability With Dose Titration and Food". To evaluate whether the tolerability of SCA-136 is improved by dosing with food or by increasing dose amounts in a step-wise fashion.
What is the current status of trial NCT00420706?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2006-12. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00420706?
The interventions under investigation include: SCA-136 (DRUG).
Who is sponsoring clinical trial NCT00420706?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.